CITI'S TAKE Exosens H1 results showed a 1% sales beat, 2% gross margin beat vs Visible Alpha consensus, 3% EBITDA beat (slightly below Citi est) and 6% EBIT beat (in line with Citi est), with 12% growth (10% like-for-like) in Amplification and 24% growth (14% like-for-like) in Detection & Imaging, helped by 2025 acquisitions. Growth was driven by strong performance in Imaging intensifying tubes in Europe, drone imaging systems and continued strength in nuclear. While FY guidance range is unchanged (Sales €5 ...